Article

FDA Approves New Anti-Opioid Addiction Drug Strength

The FDA approved a 2.9-mg/0.71-mg dosage strength of Orexo's sublingual buprenorphine/naloxone (Zubsolv).

The FDA approved a new 2.9-mg/0.71-mg dosage strength of Orexo’s sublingual buprenorphine/naloxone (Zubsolv), a partial opioid agonist indicated for the maintenance treatment of opioid dependence.

The new dosage strength will allow patients to receive their optimal dose in 1 tablet with higher bioavailability and a fast dissolve time. These features can potentially increase treatment compliance, reduce relapse rates, and improve patient outcomes, according to a manufacturer press release.

“The new tablet strength complements the existing dosage range and enables more patients to get the right dosage in only 1 tablet and thus reduces the need to combine different dosage strengths,” said Orexo president and CEO Nikolaj Sørensen in a press release. “The approval of 2.9 mg/0.71 mg brings Orexo one step closer to having the broadest dosage range within opioid addiction treatment.”

An 8.6-mg/2.1-mg dosage strength of Zubsolv was launched in the United States in March. The drug is also currently available in 5.7-mg/1.4-mg and 1.4-mg/0.36-mg strengths.

Orexo plans to launch the new 2.9 mg/0.71 mg Zubsolv during second half of 2015.

Related Videos
Happy elderly patient with medical health checkup with cardiologist or geriatric doctor. Senior old aging woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com